𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA)

✍ Scribed by M. Poisson; Y. Péréon; J. Chiras; J. Y. Delattre

Publisher
Springer US
Year
1991
Tongue
English
Weight
363 KB
Volume
10
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty patients with malignant supratentorial gliomas progressing after radiation therapy and chemotherapy with nitrosoureas received intravenous carboplatin, 450 mg/m 2. Courses of therapy were repeated every four weeks. Therapeutic evaluation was performed monthly using neurologic examination and CT scan of the brain. Of 19 patients evaluable for response, 2 (10%) responded to therapy and 6 (30%) had stable disease. The estimated median time to tumor progression for responding and stable patients was 6 months. Median duration of survival was 6 months for all patients. Of 20 patients evaluable for toxicity, none had renal or auditory toxicity. Side effects consisted of hematologic toxicity in 4 patients (20%): one patient had grade 4 toxicity requiring discontinuation of carboplatin and 3 patients had grade 2-3 toxicity.

📜 SIMILAR VOLUMES

Treatment of adults with progressive oli
Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): Preliminary results
✍ Friedman, Henry S.; Lovell, Shelley; Rasheed, Karima; Friedman, Allan H. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Background. Exploration of the role of chemotherapy in the treatment of low grade glioma, including oligodendroglioma, has been limited to the pediatric population, reflecting the sensitivity of young patients to radiationinduced toxicity and a desire to avoid this intervention (7-12). Procedure. Ni

Temozolomide in the treatment of recurre
Temozolomide in the treatment of recurrent malignant glioma
✍ Susan M. Chang; Philip Theodosopoulos; Kathleen Lamborn; Mary Malec; Jane Rabbit 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Options for chemotherapy at the time of recurrence in patients with malignant glioma are limited. The authors describe the efficacy and safety results of their institution's open‐label, compassionate‐use protocol of temozolomide for patients with recurrent malignant gliom